BMS Elects New CEO
James M. Cornelius, who has served as interim chief executive for the past eight months, has been elected chief executive officer of Bristol-Myers Squibb Company (New York, NY, www.bms.com) with a term through the date of the company's annual meeting of stockholders in 2009.
James M. Cornelius, who has served as interim chief executive for the past eight months, has been elected chief executive officer of Bristol-Myers Squibb Company (New York, NY, www.bms.com) with a term through the date of the company’s annual meeting of stockholders in 2009. Cornelius has been a member of the BMS board since January 2007. Before joining BMS, he was the chief financial officer of Eli Lilly and Company.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
